Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

START Madrid-CIOCC, Centro Integral Oncológico Clara Campal

2 abstracts

Abstract
Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).
Org: Department of Medical Oncology, Amsterdam UMC, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Department, Catalan Institute of Cancer (ICO), Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute (IDIBELL) —OncoBell, Early Phase Drug Development Program START Madrid-CIOCC, Centro Integral Oncológico Clara Campal,
Abstract
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).
Org: Institut Gustave Roussy, The Royal Marsden Hospital (Surrey), London, United Kingdom, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Hospitals Seidman Cancer Center, START San Antonio,